Aram

Aram Biosciences is a clinical-stage biotechnology company based in South Korea, dedicated to developing innovative therapies for unmet medical needs in oncology and metabolic diseases. The company's primary focus is on cancer cachexia, a complex wasting syndrome characterized by significant weight loss and muscle atrophy in cancer patients. Their lead candidate, AR-101, is a novel small molecule being evaluated for its ability to improve patient outcomes and quality of life by targeting the GDF15 pathway. Aram Biosciences leverages its expertise in translational research to advance a pipeline of therapeutics aimed at improving the standard of care for patients suffering from muscle wasting and metabolic disorders.